• 1
    Dulmen SV, Sluijs E, Dijk LV et al. Patient adherence to medical treatment: a review of reviews. BMC Health Services Research 2007;7:55.
  • 2
    David AS. The clinical importance of insight: an overview. In: Amador XF, David AS (eds). Insight and psychosis: awareness of illness in schizophrenia and related disorders, 2nd ed. Oxford: Oxford University Press, 2004:359-92.
  • 3
    Kemp R, Kirov G, Everitt B et al. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998;172:413-9.
  • 4
    O'Donnell C, Donohoe G, Sharkey L et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003;327:834-6.
  • 5
    Gray R, Wykes T, Edmonds M et al. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial. Br J Psychiatry 2004;185:157-62.
  • 6
    Gray R, Leese M, Bindman J et al. Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br J Psychiatry 2006;189:508-14.
  • 7
    Staring ABP, van der Gaag M, Koopmans GT et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2010;197:448-55.
  • 8
    Priebe S, Burton A, Ashby D et al. Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients – cluster randomised controlled trial (FIAT). BMC Psychiatry 2009;9:61.
  • 9
    Patel MX, deZoysa N, Bernadt M et al. Are depot antipsychotics more coercive than tablets? The patient's perspective. J Psychopharmacol 2010;24:1483-9.
  • 10
    Patel MX, De Zoysa N, Bernadt M et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009;23:789-96.
  • 11
    Patel MX, Matonhodze J, Baig MK et al. Increased use of antipsychotic long acting injections with community treatment orders. Ther Adv Psychopharmacol 2011;1:37-45.